We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Urine Samples Screened for Chlamydial Urogenital Disease

By LabMedica International staff writers
Posted on 12 Jul 2010
Cervical swabs and urine samples are used to screen women for bacterial diseases that are sexually transmitted. More...


The Chlamydiaceae are gram-negative, obligate intracellular bacteria that form characteristic intracellular inclusions that are observable in cell culture by fluorescence microscopy after the application antigen-specific staining.

Although historically culture has been the "gold standard” for detection of Chlamydia trachomatis the enhanced sensitivity of amplified methods has led to their increasing adoption and in turn contributed to the rise in the number of reported cases of infection.

In a study carried out at the Haukeland University Hospital (Bergen, Norway), both cervical swabs and urine samples from women enrolled in a sexually transmitted infection clinic were screened for C. trachomatis. The molecular diagnostic test used was the Becton Dickinson ProbeTec (BDPT) Strand Displacement Assay (SDA) (Becton Dickinson, Franklin Lakes, NJ, USA). A total of 1,809 specimens were collected from 603 patients. Eighty women (13.4%) were positive for C. trachomatis. Among these, BDPT identified 72 and 73 as positive in cervix and urine samples, respectively. In cases of discrepant test results from a given patient, both samples were retested by another commercial kit, Cobas TaqManCT, (Roche Diagnostics, Basel, Switzerland) and an in-house polymerase chain reaction (PCR)-method. The sensitivity and specificity of BDPT was excellent regardless of sample category.

This study indicates that urine specimens are adequate for screening high-risk groups for C. trachomatis by the SDA method (BDPT). Urine samples may be particularly important in screening young people who are asymptomatic. Such an approach may facilitate early detection and treatment of the target groups for screening, and be cost-effective for patients and the health services.

It is estimated that 89 million new cases of genital Chlamydia infection occur worldwide in the age group 15 to 49 years and in the US it is estimated that four million cases transpire annually. In women, cervicitis, pelvic inflammatory disease (PID), ectopic pregnancy, and acute or chronic pelvic pain are frequent complications. C. trachomatis is also an important neonatal pathogen, where it can lead to infections of the eye (trachoma) and pulmonary complications. The bacterium can cause prostatitis and epididymitis in men.

Related Links:

Haukeland University Hospital
Becton Dickinson
Roche Diagnostics



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.